Expedition Therapeutics

About Expedition Therapeutics

Expedition Therapeutics is a biotech company focused on developing novel treatments for inflammatory and respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). Their mission is to redefine care by advancing therapies that target fundamental disease mechanisms, aiming to transform patient care worldwide.

Products & Services

EXPD-101:A next-generation oral DPP1 inhibitor designed to selectively block neutrophil serine proteases (NSPs) causing airway damage in COPD. It targets neutrophilic inflammation with high potency, safety, and once-daily dosing, currently advancing to a global Phase 2 trial for COPD with potential expansion to other neutrophil-driven diseases.

Specialties

Inflammatory and Respiratory Diseases Chronic Obstructive Pulmonary Disease (COPD) Neutrophilic Inflammation DPP1 Inhibitors Drug Discovery and Clinical Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 165000000 MR: - FA: 165 million FAN: 165000000	D: 2025-10-09 FD: 2025-10-09	10 investors

Series A Latest

2025-10-09

$165.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gorjan Hrustanovic

Partner at BVF Partners

R

Regina Salvat

Principal

Y

Yi Larson

President & Chief Executive Officer

A

Andrew Cheng

Board Chairman

J

James Chalmers

Professor, University of Dundee, Asthma and Lung UK Chair of Respiratory Research

E

Erin Lavelle

Independent Director; former COO/CFO of ProfoundBio

View 14 more team members with Pro

Unlock Full Team Directory

Recent News